Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cancer: experimental drug CR-001 enters human trials

NCT ID NCT07335497

Disease control Sponsor: Crescent Biopharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 13 times

Summary

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 290 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * For Backfill and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy * Tumor Indication specific inclusion criteria: * For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types: * Hepatocellular carcinoma * Biliary tract cancer * Endometrial carcinoma * Cervical cancer * Ovarian cancer * Gastric or gastroesophageal cancer * Colorectal cancer * Non-small cell lung cancer Key Exclusion Criteria * Has malignancies other than disease under study within the past 3 years * Has conditions requiring treatment with clinically significant or increasing doses of systemic steroid therapy * Has not adequately recovered from recent major surgery * Has ongoing clinically significant toxicity related to prior therapy * Has active central nervous system (CNS) metastases * Has active autoimmune disease requiring systemic therapy in the past 2 years (replacement therapy is permitted) * Has a history of serious Grade ≥ 3 immune-related adverse event (irAE) * Has a history of noninfectious pneumonitis/interstitial lung disease * Has an active severe infection * Has received a live or attenuated vaccine within 30 days of the first dose * Has undergone prior allogeneic stem cell or solid organ transplantation * Has protocol-specified events related to gastrointestinal perforation, surgery, wound healing complications, and bleeding * Has clinically significant cardiovascular disease NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer cervical cancer colorectal cancer endometrial carcinoma gastroesophageal cancer hepatocellular carcinoma metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced / metastatic solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Study Site

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • Clinical Study Site

    RECRUITING

    Los Angeles, California, 90033, United States

  • Clinical Study Site

    RECRUITING

    Denver, Colorado, 80218, United States

  • Clinical Study Site

    RECRUITING

    Washington D.C., District of Columbia, 20009, United States

  • Clinical Study Site

    RECRUITING

    Orlando, Florida, 32827, United States

  • Clinical Study Site

    RECRUITING

    Sarasota, Florida, 34236, United States

  • Clinical Study Site

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Clinical Study Site

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Clinical Study Site

    RECRUITING

    New York, New York, 10029, United States

  • Clinical Study Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Clinical Study Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Clinical Study Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Clinical Study Site

    RECRUITING

    Dallas, Texas, 75230, United States

  • Clinical Study Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Clinical Study Site

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Clinical Study Site

    WITHDRAWN

    South Brisbane, Queensland, 4101, Australia

  • Clinical Study Site

    RECRUITING

    Dublin, Ireland, Ireland

  • Clinical Study Site

    RECRUITING

    Milan, Milano, 20089, Italy

  • Clinical Study Site

    RECRUITING

    Candiolo, Torino, 10060, Italy

  • Clinical Study Site

    RECRUITING

    Cluj-Napoca, Cluj, 400015, Romania

  • Clinical Study Site

    RECRUITING

    Bucharest, 022328, Romania

  • Clinical Study Site

    RECRUITING

    Seoul, Seoul, 03080, South Korea

  • Clinical Study Site

    RECRUITING

    Seoul, Seoul, 03722, South Korea

  • Clinical Study Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Clinical Study Site

    RECRUITING

    Songpa-dong, Seoul, 05505, South Korea

  • Clinical Study Site

    RECRUITING

    Seongnam-si, 13620, South Korea

  • Clinical Study Site

    RECRUITING

    Barcelona, Barcelona, 08023, Spain

  • Clinical Study Site

    RECRUITING

    Logroño, La Rioja, 26006, Spain

  • Clinical Study Site

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Clinical Study Site

    RECRUITING

    Madrid, Madrid, 28223, Spain

  • Clinical Study Site

    RECRUITING

    Manchester, Greater Manchester, M20 4 BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.